Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Laure-Anne Teuwen, Tom Van den Mooter & Luc Dirix. (2015) Management of pulmonary toxicity associated with targeted anticancer therapies. Expert Opinion on Drug Metabolism & Toxicology 11:11, pages 1695-1707.
Read now
Read now
David Aguiar-Bujanda, María Jesús Blanco-Sánchez, María Hernández-Sosa, Saray Galván-Ruíz & Samuel Hernández-Sarmiento. (2015) Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma. Cancer Management and Research 7, pages 319-330.
Read now
Read now
Hervé Ghesquières. (2015) Pneumonitis following immunochemotherapy with rituximab: a new well-designed retrospective study to better assess the risks. Leukemia & Lymphoma 56:6, pages 1577-1578.
Read now
Read now
Giselle Salmasi, Michael Li, Vithika Sivabalasundaram, Tony Panzarella, Richard Tsang, Vishal Kukreti, Michael Crump & John Kuruvilla. (2015) Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab. Leukemia & Lymphoma 56:6, pages 1659-1664.
Read now
Read now
Anna M Sadowska, Pol Specenier, Paul Germonpre & Marc Peeters. (2013) Antineoplastic therapy-induced pulmonary toxicity. Expert Review of Anticancer Therapy 13:8, pages 997-1006.
Read now
Read now
Kenji Hashimoto, Yukio Kobayashi, Yoshitaka Asakura, Masakazu Mori, Teruhisa Azuma, Dai Maruyama, Sung-Won Kim, Takashi Watanabe & Kensei Tobinai. (2010) Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy. Leukemia & Lymphoma 51:10, pages 1816-1821.
Read now
Read now
C. Vulsteke, D. Dierickx, E. Verbeken, P. Wolter, J. Thomas & P. Schöffski. (2010) Rituximab-induced fatal interstitial pneumonitis: case report. Leukemia & Lymphoma 51:3, pages 546-548.
Read now
Read now
Dennis A Eichenauer, Andreas Engert & Holger Schulz. (2009) Expanded use of rituximab in the management of non-Hodgkin lymphoma. OncoTargets and Therapy 2, pages 189-197.
Read now
Read now
Ron Ram, Isaac Ben-Bassat, Ofer Shpilberg, Aaron Polliack & Pia Raanani. (2009) The late adverse events of rituximab therapy – rare but there!. Leukemia & Lymphoma 50:7, pages 1083-1095.
Read now
Read now
Articles from other publishers (37)
Davide Colombi, Flavio Cesare Bodini, Nicola Morelli, Mario Silva, Gianluca Milanese, Luigi Cavanna & Emanuele Michieletti. (2021) COVID-19 outbreak in Italy: Clinical-radiological presentation and outcome in three oncologic patients. Journal of Infection and Chemotherapy 27:1, pages 99-102.
Crossref
Crossref
Cong Li, Fangxiao Lu, Tao Lei, Haifeng Yu, Xi Chen, Shuailing Peng, Shuiyun Han & Haiyan Yang. (2020) Prophylactic antibiotic treatment with TMP-SMX decreased the incidence of interstitial pneumonia in patients with B-cell lymphoma on chemotherapy. BMC Cancer 20:1.
Crossref
Crossref
Meixin Zhao & Weifang Zhang. (2018) Early detection value of 18F-FDG-PET/CT for drug-induced lung injury in lymphoma. Annals of Hematology 98:4, pages 909-914.
Crossref
Crossref
Yuchen Wu, Xuefei Sun, Jing Liu, Jun Qian, Xueyan Bai, Yuedan Chen & Yuanbo Liu. (2018) Interstitial pneumonitis during rituximab-containing chemotherapy for primary central nervous system lymphomas: a case report and review of literature. Chinese Neurosurgical Journal 4:1.
Crossref
Crossref
Kimberly Keefer, Regis Bender, Jason Liao, Jeffrey Sivik & Andry Van de Louw. (2018) Characteristics of pulmonary complications in non-Hodgkin’s lymphoma patients treated with rituximab-containing chemotherapy and impact on survival. Annals of Hematology 97:12, pages 2373-2380.
Crossref
Crossref
Mingxiao Lang, Jingwei Yu, Xianhuo Wang, Zheng Song, Lanfang Li, Lihua Qiu & Huilai Zhang. (2018) Immunochemotherapeutic increase of peripheral absolute monocyte count predicts interstitial pneumonia in lymphoma patients. Hematological Oncology 36:5, pages 779-785.
Crossref
Crossref
Akash Jain, Vickie R. Shannon & Ajay Sheshadri. (2018) Pneumonitis After Precision Oncology Therapies: A Concise Review. Journal of Immunotherapy and Precision Oncology 1:1, pages 26-37.
Crossref
Crossref
Ting Zhou, Qian Shen, Hui Peng, Tengfei Chao, Lihong Zhang, Liu Huang, Kaixiang Yang, Sudip Thapa, Shiying Yu & Yongsheng Jiang. (2017) Incidence of interstitial pneumonitis in non-Hodgkin’s lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab. Annals of Hematology 97:1, pages 141-147.
Crossref
Crossref
Wei Ping Liu, Xiao Pei Wang, Wen Zheng, Yan Xie, Mei Feng Tu, Ning Jing Lin, Ling Yan Ping, Zhi Tao Ying, Chen Zhang, Li Juan Deng, Ning Ding, Xiao Gan Wang, Yu Qin Song & Jun Zhu. (2017) Incidence, clinical characteristics, and outcome of interstitial pneumonia in patients with lymphoma. Annals of Hematology 97:1, pages 133-139.
Crossref
Crossref
Daniel Franzen, Adrian Ciurea, Daniel J. Bratton, Christian F. Clarenbach, Tsogyal D. Latshang, Erich W. Russi, Diego Kyburz & Malcolm Kohler. (2016) Effect of rituximab on pulmonary function in patients with rheumatoid arthritis. Pulmonary Pharmacology & Therapeutics 37, pages 24-29.
Crossref
Crossref
M. Farooqui, K. Alsaad, N. Aloudah & H. Alhamdan. (2015) Treatment-Resistant Recurrent Membranoproliferative Glomerulonephritis in Renal Allograft Responding to Rituximab: Case Report. Transplantation Proceedings 47:3, pages 823-826.
Crossref
Crossref
Suhas Aagre, Apurva Patel, Pradip Kendre & Asha Anand. (2015) Rituximab-induced interstitial lung disease in a patient with follicular lymphoma: A rare case report. Lung India 32:6, pages 620.
Crossref
Crossref
Rianne Wittenberg, Santiago Rossi & Cornelia Schaefer-Prokop. 2015. Imaging of Complications and Toxicity following Tumor Therapy. Imaging of Complications and Toxicity following Tumor Therapy
129
145
.
Uma Maheswari Krishnaswamy, Vinayak V. Maka, Murali Subramanian, Rohith Chitrapur & Nalini Kilara. (2014) Rituximab Induced Interstitial Lung Disease in Patients with Non-Hodgkin’s Lymphoma: A Clinical Study of Six Cases and Review of the Literature. Lymphoma 2014, pages 1-6.
Crossref
Crossref
Jeremy M. Clain, Rodrigo Cartin-Ceba, Fernando C. Fervenza & Ulrich Specks. (2013) Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. Therapeutic Advances in Musculoskeletal Disease 6:2, pages 58-74.
Crossref
Crossref
Ladan Zand, Ulrich Specks, Sanjeev Sethi & Fernando C. Fervenza. (2014) Treatment of ANCA-Associated Vasculitis: New Therapies and a Look at Old Entities. Advances in Chronic Kidney Disease 21:2, pages 182-193.
Crossref
Crossref
Yongkang Wu, Yongqian Jia, Juan Xu, Xiao Shuai & Yu Wu. (2013) Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature. Journal of Clinical Pharmacy and Therapeutics 38:3, pages 249-253.
Crossref
Crossref
Seung-Ick Cha, Keum-Ju Choi, Kyung-Min Shin, Jaekwang Lim, Seung-Soo Yoo, Jaehee Lee, Shin-Yup Lee, Chang-Ho Kim & Jae-Yong Park. (2013) Risk Factors for Rituximab-Induced Interstitial Lung Diseases in Patients with Malignant Lymphoma. Respiration 85:2, pages 175-175.
Crossref
Crossref
Wei-Liang Chen, Yu-Tzu Tsao, Tsun-Hou Chang, Tsu-Yi Chao, Woei-Yau Kao, Yeu Chin Chen & Ching-Liang Ho. (2013) Impact of Interstitial Pneumonia on the Survival and Risk Factors Analysis of Patients with Hematological Malignancy. BioMed Research International 2013, pages 1-9.
Crossref
Crossref
Linda Lee, Michael Crump, Sara Khor, Jeffrey S. Hoch, Jin Luo, Karen Bremner, Murray Krahn & David C. Hodgson. (2012) Impact of rituximab on treatment outcomes of patients with diffuse large b‐cell lymphoma: a population‐based analysis. British Journal of Haematology 158:4, pages 481-488.
Crossref
Crossref
T. Shen & S. Braude. (2012) Obliterative bronchiolitis after rituximab administration: a new manifestation of rituximab-associated pulmonary toxicity. Internal Medicine Journal 42:5, pages 597-599.
Crossref
Crossref
A. V. Hadjinicolaou, M. K. Nisar, H. Parfrey, E. R. Chilvers & A. J. K. Ostor. (2011) Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology 51:4, pages 653-662.
Crossref
Crossref
N. Child, M. O'Carroll & L. Berkahn. (2012) Rituximab-induced interstitial lung disease in a patient with immune thrombocytopenia purpura. Internal Medicine Journal 42:3, pages e12-e14.
Crossref
Crossref
Hyo Jae Kang, Jong Sun Park, Dong-Wan Kim, Jinwoo Lee, Yun Jeong Jeong, Sun Mi Choi, Sang-Min Lee, Seok-Chul Yang, Chul-Gyu Yoo, Young Whan Kim, Sung Koo Han & Jae-Joon Yim. (2012) Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients. Respiratory Medicine 106:3, pages 443-450.
Crossref
Crossref
Ahmet B. Ergin, Nancy Fong & Hamed A. Daw. (2012) Rituximab-Induced Bronchiolitis Obliterans Organizing Pneumonia. Case Reports in Medicine 2012, pages 1-4.
Crossref
Crossref
Harumi Kato, Kazuhito Yamamoto, Hirofumi Taji, Yasuhiro Oki, Dai Chihara, Masao Seto, Yoshitoyo Kagami & Yasuo Morishima. (2011) Interstitial Pneumonia After Autologous Hematopoietic Stem Cell Transplantation in B-Cell Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia 11:6, pages 483-489.
Crossref
Crossref
Roberto Perez-Alvarez, Marta Perez-de-Lis, Candido Diaz-Lagares, Jose M. Pego-Reigosa, Soledad Retamozo, Albert Bove, Pilar Brito-Zeron, Xavier Bosch & Manuel Ramos-Casals. (2011) Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases. Seminars in Arthritis and Rheumatism 41:2, pages 256-264.
Crossref
Crossref
Yu-Chung Huang, Chia-Jen Liu, Chun-Yu Liu, Jih-Tung Pai, Ying-Chung Hong, Hao-Wei Teng, Liang-Tsai Hsiao, Ta-Chung Chao, Jyh-Pyng Gau, Jin-Hwang Liu, Hui-Chi Hsu, Tzeon-Jye Chiou, Po-Min Chen, Yuan-Bin Yu & Cheng-Hwai Tzeng. (2011) Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Annals of Hematology 90:10, pages 1145-1151.
Crossref
Crossref
Daan Dierickx, André Delannoy, Khalid Saja, Gregor Verhoef & Drew Provan. (2011) Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. American Journal of Hematology 86:3, pages 278-291.
Crossref
Crossref
D. Spoerl & Andreas J. Bircher. 2011. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
769
814
.
Philippe Camus. 2011. Pulmonary Involvement in Patients with Hematological Malignancies. Pulmonary Involvement in Patients with Hematological Malignancies
387
423
.
Olivier Thaunat, Emmanuel Morelon & Thierry Defrance. (2010) Am“B”valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis. Blood 116:4, pages 515-521.
Crossref
Crossref
Larry C. Lands. (2010) New therapies, new concerns: rituximab-associated lung injury. Pediatric Nephrology 25:6, pages 1001-1003.
Crossref
Crossref
Samantha M. Jaglowski & John C. Byrd. (2010) Rituximab in Chronic Lymphocytic Leukemia. Seminars in Hematology 47:2, pages 156-169.
Crossref
Crossref
Martin Bitzan, Mark Anselmo & Lucy Carpineta. (2010) Reply: Rituximab-induced pneumonitis: Steroid therapy or not?. Pediatric Pulmonology 45:4, pages 414-416.
Crossref
Crossref
Maajid Mumtaz Peerzada, Timothy P. Spiro & Hamed A. Daw. (2010) Pulmonary toxicities of biologics: a review. Anti-Cancer Drugs 21:2, pages 131-139.
Crossref
Crossref
Thomas Fehr, Barbara Rüsi, Andreas Fischer, Helmut Hopfer, Rudolf P. Wüthrich & Ariana Gaspert. (2009) Rituximab and Intravenous Immunoglobulin Treatment of Chronic Antibody-Mediated Kidney Allograft Rejection. Transplantation 87:12, pages 1837-1841.
Crossref
Crossref